Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Dianthus Therapeutics, Inc. /DE/
| Metric | Dianthus Therapeutics, Inc. /DE/ DNTHHealthcare |
|---|---|
| Quality Score | 47 / 100 |
| Revenue (latest) | $2M |
| Net income (latest) | −$162M |
| Operating margin | −8739.3% |
| Net margin | −7973.3% |
| Return on equity | −32.9% |
| Return on assets | −30.6% |
| Return on capital (ROCE) | −35.6% |
| Debt / equity | 0.08× |
| Revenue growth (YoY) | −67.3% |
| Altman Z″ (distress) | 14.17 |
| Accruals / assets | −6.3% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.